Arana [ASX: ARA] has engineered an improved version of the VEGF-D antibody owned by Circadian Technologies [ASX: CIR] subsidiary Vegenics.

The antibody, designed to treat certain cancers, was modified into a humanised version using Arana's Superhumanisation technology.

It was then further refined using the company's EvoGene optimisation technology.

Conversion into humanised form will ensure that the risks of rejection of the treatment are minimised.

Circadian will shortly pay Arana milestone payments for the project, and Arana will be eligible to further milestone payments as the project advances through the various testing stages.